Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
shane622 can you post documents on the done deal.
We still have two others that need to get out for good. LMAO.
I am long in AMBS but thought I'd bring this and let everyone know that we've got competition and MJF has also funded SNY. I found this article in the internet.
Parkinson's - which afflicts about a million Americans, including boxing legend Muhammad Ali and Michael J Fox - is a progressive neurological disorder that mostly strikes people over 50, causing tremors, slow movement and other problems.
It occurs when nerve cells in the brain that produce dopamine, a chemical that helps control muscle movement, are slowly destroyed.
Here is a list of companies attempting to develop a cure:
Living Cell Technologies Limited (LVCLY.OB)
Living Cell Technologies Limited (LVCLY) has received ethical approval for its NTCELL. In a controlled trial for NTCELL, a Parkinson's-like condition was produced in non-human primates using drugs which selectively deplete dopamine-producing neurons in the brain. Reduction of dopamine levels in the brain is a hallmark of Parkinson's disease in humans. The non- human primates developed movement disorders and neurological deficits similar to Parkinson's patients. NTCELL was then implanted into the affected brain areas and within two weeks, improvements in both motor abnormalities and neurological function were observed in the NTCELL treated subjects compared to controls. These improvements increased and persisted for at least six months beyond the NTCELL implant, the end-point of the study. Microscopic analysis of both treated and untreated brain regions clearly showed an increase in the number of dopamine producing neurons in the NTCELL treated subjects compared to controls. In addition, there was no cellular or pathological evidence of inflammation or other adverse event.
These results from February 2012 were consistent with all Living Cell Technologies' prior pre-clinical NTCELL studies in other small animal models of Parkinson's.
Sanofi-Aventis (SNY)
The drug company Sanofi recently entered into a collaboration with the Michael J Fox Foundation - MJFF - to conduct a clinical trial to assess the safety of a new drug, a type of inhibitor called phosphodiesterase (coded AVE8112). Todd Sherer, Ph.D., Chief Executive Officer of MJFF, said that the drug had: "Shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson's disease, an area of unmet need where a new treatment could make a tangible difference in patients' lives."
Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics is pursuing orally administered drugs called pharmacological chaperones to treat a broad range of diseases of neuro-degeneration. Amicus is targeting the GBA1 mutation that has been identified as the most common genetic factor of Parkinson's.
Amicus is currently undergoing preclinical studies to evaluate two of these chaperones, AT2101 and AT3375, in an effort to target an enzyme that is at the root cause of the disease. Amicus received a grant from the Michael J Fox Foundation to pursue this potential cure.
Impact Laboratories (IPXL)
Last month the FDA extended its review of Impax Labs Parkinson's drug, Rytary, by three months until Jan. 21. The primary endpoint of the Rytary (IPX066) trial in 2011 was the percentage of "off time"--when patients' medication effect has worn off and there is a return of Parkinson's symptoms--during waking hours. Rytary demonstrated a 37 percent improvement from baseline compared to a 17 percent improvement from baseline for the standard treatment.
"Consistent with our Phase II findings, these data show IPX066 provides a robust level of efficacy across a range of PD clinical and QOL measures, which represents a potentially significant improvement over existing treatment options," said Impax CSO Dr. Suneel Gupta.
Amarantus BioSciences (AMBS.OB)
Amarantus' proprietary anti-apoptosis therapeutic protein MANF, recently announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data demonstrated that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF (another therapeutic protein in Phase II trials) did not.
Dr. Joseph Rubinfeld, co-founder of Amgen, stated "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Amarantus is also a recipient of a grant from the Michael J Fox Foundation.
NOTE:
Please note that both Living Cell and Amarantus are penny stocks and are subject to wild swings in their prices. Both are startup companies and may lack the resources to bring their drugs to market, therefore potentially subjecting shareholders to dilution.
7 people decided to get LVCLY.PK articles by email alert
Get email alerts on LVCLY.PK »
About this article
Retailers IMO can't only the MM's
You have a point in regards to the over exaggerated repeated pumping of news, but then, we just can trust anyone, am I right, "anyone" including you my friend, so therefore; I suggest to all longs including myself, to wait for fresh news which I truly believe we'll hear anytime soon. All I want is the best for everyone, and I believe we have a good one with AMBS. I'll catch you all later, I'm going shrimp fishing.
We need the Doc to come up with an intelligent post, it's been a while Doc since you posted, seems to be that we only read pumpers with continuous old news, I'm long but this has gotten out of hand with the same old news. If we only stayed shut and wait to we hear new news then we can continue, but it's just boring to hear bla bla this, bla bla, that's enough of the crapola, we longs know the facts, let's calm down and wait for coming news. stop the pumping, smart investors are tired of hearing the same old, they and I want fresh and factual news.
Jup as i do recall about 3 years ago I was reading about another Health Science Group located in California, I believe they're located in LA and they do sell Vitamins and health supplements.
Jup I find this no bid problem to be a serious problem, the MM's are manipulating penny stocks too a point which I find to be illegal to the core, this needs to stop but unfortunately the SEC gives a hoot about pinks and I wouldn't be surprised one bit if they are also involved in the MM scams, JMHO.
LMAO, did you just say, If it's breaking news i get back in? Ha ha haha, of course you will buddy boy, I sure bet you will.
Yea right, and an MM devil just text me and said Solantey is out and about trying to scare longs out of their shares, LMAO.
Looks like smoke and the Doc are both gone.
WTF!!! is going on here.
What happened with the Doc, where is he, thought he would be commenting about today's news.
Looks like shorty could be bent over with their pants down?, ROFLMAO, good one there mwab52.
I wouldn't want to imagine HESG dumping shares in a more conservative, tactical, slowly but surely kind of way.
Does anyone know if these 1's that are hitting the bid retail or is it that the company is selling 1's.
What is going on with all this volume today.
Soon it will start going back up to new highs.
We already know it.
Peeps just wanting to say that I have an old friend that back in the day when Apple shares where costing 6 dollars and change, this friend of mine bought 10 thousand shares and he still owns them till today, he's worth a few million I guess, ha, ha. Can we expect something similar with AMBS, maybe not to the extreme but who knows.
I just hope so, I don't have too many shares, but like you said, you never know what could happen.
Doc. so what you're saying is "if" AMBS is bought out by a big Pharma what are the expectations of a PPS bay out.
Doc. and I believe as well as many other investors that AMBS will most likely be worth more than 510 million, making it a more higher PPS if they get bought out, JMHO.
HA HA HA HA, what's up Stevie boy, after so many years, you're still the same old Stevie, LMAO.
Need to add the number signs to the right of the symbol.
Has anyone been able to buy ones.
Great DD Shanon1.
Hey Jup that's what pisses me off, we had news a few days ago with large amounts of volume and we couldn't hold onto the 2's, by now we should have been seeing 3's and 4's. Today we get small increments and we're seeing 2's. I've been held for a while now to 1 post a day so I can't answer back.
Oil fields, apps and gold just to name a few and all are scams.
Where the hell are all these 1's coming from, are those peeps selling at one or company dumping shares.
I'm CEO and President of my own investment company and I also own two other small company's, and only my wife knows of those two why should the VP of my company know about the other two.
Wizard what are those negative 9999.99 all about is it that they are wanting shares, what is that all about.
zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz
Lets hope for the best for everyone invested in HESG, damn I've been wanting to replace mu old skiff with a new Maverick so I can take advantage of fishing off of Flamingo Bay.
Funny to know that someone painted it at 2 and another stock I have is also expected news and painted back at 2 with a 911.
5 fre*** dollars, HA!!!!!
Paint job.
I hate to say it but this smell like a dead horse.
Could be these MM's POS's want you to buy a 2.
This sucks, this smells like dilution to me, no question about it.